37 trends tracked about this subject — the full history, oldest to newest below.
The FDA is requiring all GLP-1 drug makers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.
European shares rose over 1% on Monday as Democrats' sweep of the U.S. Congress triggered a rotation out of tech and into banks, while falling oil prices and bond yields eased inflation worries.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Novo Nordisk raises its 2026 outlook and shares surge as the Wegovy weight-loss pill rollout accelerates.
A US judge has ruled against Novo Nordisk, allowing Eli Lilly to continue running advertisements for its weight-loss medications.
Novo's next-generation obesity drug CagriSema showed 25 percent weight loss in women in late-stage analysis.
Novo Nordisk and Eli Lilly receive positive news amid ongoing developments in drug discovery and aging research.
Recent studies indicate that popular GLP-1 weight-loss medications like Ozempic and Mounjaro may also slow biological aging.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Real-world study data reveals patients switching from obesity injections to Novo Nordisk's oral Wegovy pill continue to lose weight.
GLP-1 medications are shifting from clinical obesity treatments for patients to lifestyle products for customers, amid a surge in oral pill options.
Novo Nordisk strikes a $1.3 billion deal with Nanexa to secure long-acting obesity injection technology.
Novo Nordisk unveils its next growth engine at Capital Markets Day as competitor Eli Lilly gains ground in GLP-1s.
Major drugmakers Novo Nordisk and Eli Lilly face numerous lawsuits alleging popular GLP-1 medications cause sudden vision loss.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Novo Nordisk shares slide despite aggressive obesity targets as investors demand a broader long-term strategy.
Recent studies indicate that popular weight-loss treatments manufactured by Novo Nordisk and Eli Lilly retain efficacy at reduced doses.
Novo Nordisk signs a licensing agreement worth up to $1.4 billion with Orbis Medicines to develop oral therapeutics.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
The failure of heart drug trials from pharmaceutical giants Novartis and Novo Nordisk creates a significant setback for a promising field of medicine.
Novo Nordisk faces a divergent clinical outlook as its pediatric obesity trials succeed while heart drug programs for CKD suffer setbacks.
Novo Nordisk has halted two clinical trials for Ziltivekimab, an experimental cardiovascular drug designed to reduce inflammation.
Novo Nordisk's Wegovy shows weight-loss results in young children during trial data releases.
Novo Nordisk faces a diverging trajectory as it meets pediatric obesity goals but terminates two heart disease drug trials.
Novo Nordisk has terminated two additional phase 3 trials of its cardiovascular drug ziltivekimab due to futility, impacting its growth strategy.
Novo Nordisk’s once‑dominant GLP‑1 weight‑loss line now faces a fierce showdown with Eli Lilly, sparking questions about Europe’s biotech edge.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Novo Nordisk shares decline despite Q2 profit beats and raised forecasts, amid intensifying competition with Eli Lilly.
Pharmaceutical giant Novo Nordisk faces a significant setback following the failure of a late-stage cardiovascular drug trial.
Novo Nordisk faces a significant setback in expanding beyond obesity as a key phase 3 trial delivers disappointing results.
Novo Nordisk has filed a lawsuit against Eli Lilly over allegations of deceptive and misleading advertising regarding GLP-1 weight-loss drugs.
Novo Nordisk has launched a legal offensive against Eli Lilly, alleging that the competitor's GLP-1 weight-loss drug advertising is deceptive.
FDA’s new peptide panel sparks regulatory debate as biotech giants Lilly and Novo eye the next health wave.
Novo Nordisk and Vivani are partnering to develop a long-acting semaglutide implant designed to improve weight loss adherence for up to a year.
Medicare has introduced $50 prescriptions for GLP-1 medications, signaling a potential shift in the US healthcare and pharmaceutical landscape.
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.